BMC Cancer

Table 1 Clinico-pathological characteristics of the investigated cohort (n = 130)

From: Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer

		miR-34a expression^d							miR-34a promoter methylation
		n. (%)		Missing	Median	p-value^b	n. (%)		Missing	Negative	Positive	p-value^c
Presence of disease	healthy samples	8	5,7 %	0	1,39		8	5,7 %	8	-	-
Presence of disease	cancers	133	94,3 %	38	0,39	0.002 ^f	133	94,3 %	37	61	34	-
Age	<62.3 years^a	66	49,6 %	16	0,44		66	49,6 %	19	30	17
	>62.3 years	67	50,4 %	22	0,33	0.136	67	50,4 %	18	31	17	0.939
Histotype	serous	67	50,4 %	22	0,33		67	50,4 %	14	32	21
	endometrioid	24	18,0 %	6	0,5		24	18,0 %	6	12	5
	mucinous	37	27,8 %	10	0,4		37	27,8 %	15	15	7
	clear cell	5	3,8 %	0	1,07	0.215	5	3,8 %	2	2	1	0.799
FIGO stage	early stages (I-II)	31	23,3 %	9	0,4		31	23,3 %	10	15	6
FIGO stage	late stages (III-IV)	102	76,7 %	29	0,36	0.192	102	76,7 %	27	46	28	0.434
Grading	1	4	3,0 %	1	1,43		4	3,0 %	0	4	0
	2	74	55,6 %	23	0,44		74	55,6 %	21	37	15
	3	55	41,4 %	14	0,33	0.028 ^e	55	41,4 %	16	20	19	0,046^e
Residual disease	RD = 0	49	37,1 %	9	0,42		49	37,1 %	19	23	7
Residual disease	RD > 0	83	62,9 %	29	0,36	0.491	83	62,9 %	17	38	27	0,085
Type	type 1	91	68,4 %	26	0,43		91	68,4 %	28	45	17
Type	type 2	42	31,6 %	12	0,28	0.037 ^e	42	31,6 %	9	16	17	0,020 ^e
Serous	LGSC	13	29,5 %	6	0,77		13	29,5 %	2	8	3
Serous	HGSC	31	70,5 %	12	0,21	0.004 ^f	31	70,5 %	7	12	12	0,207
p53 mutation	no	30	33,0 %	12	0,7		30	33,0 %	6	18	6
p53 mutation	yes	61	67,0 %	19	0,33	0.003 ^f	61	67,0 %	18	22	20	0,07

^aMedian value in cancer cohort. ^bMann–Whitney test or Kruskal-Wallis test ^cchi-square test. ^dArbitrary units normalized to TBP. ^eSignificant at the 0.05 level (2-tailed). ^fSignificant at the 0.01 level (2-tailed)

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com